FDA: risk of fluoroquinolone for diabetics



[ad_1]

Active substances used as broad-spectrum antibiotics – ciprofloxacin, norfloxacin, enoxacin, ofloxacin, levofloxacin and moxifloxacin – may cause side effects that may cause permanent impairment. Possible tendon damage in the form of inflammation or cracks. Achilles tendon rupture is considered particularly dangerous and occurs with increased risk in people aged 60 and over. The undesirable effect can occur a few hours after ingestion or up to four weeks after the end of treatment. Based on a review, the FDA now warns of the occurrence of hypoglycemic comas as a drug-related adverse reaction among fluoroquinolones ciprofloxacin, gemifloxacin, levofloxacin, moxifloxacin, ofloxacin and delelafloxacin. The latter was approved in June 2017 and has not been included in the evaluation, but the agency attributes the same side effects to the drug as it belongs to the same clbad. A change in the safety mark should be made for the six drugs.

Hypoglycemic coma, which in some cases resulted in death, is currently not listed in any product and product information. However, the risk of hypoglycemia, which may be badociated with the use of fluoroquinolones, can be found in some product information. It has been reported that moxifloxacin causes dysglycemia, which is mainly observed in elderly diabetics who are treated with oral antidiabetic or insulin. For four fluoroquinolones, an interaction with sulfonylureas is described

[ad_2]
Source link